Teriparatide biosimilar (Almaject)

特立帕肽生物类似药（Almaject）

Report date: 2024/06/07 14:43:12

Base Information

Drug NameTeriparatide biosimilar (Almaject)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionParathyroid hormone receptor agonistsParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis, PostmenopausalOsteoporosis
Global Approved IndicationsOsteoporosis, PostmenopausalOsteoporosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/06/04
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlmaject Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlmaject Inc
Inactive CompaniesN/A
Active IndicationsOsteoporosis, PostmenopausalOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A